Citigroup
MRNA icon

Citigroup’s Moderna MRNA Stock Holding History

Citigroup’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$214M Sell
4,209,500
-1,432,800
-25% -$66.8M 0.09% 204
2025
Q4 		$166M Buy
5,642,300
+5,442,300
+2,721% +$148M 0.07% 241
2025
Q3 		$5.17M Buy
200,000
+170,000
+567% +$4.74M ﹤0.01% 1953
2025
Q2 		$828K Sell
30,000
-83,800
-74% -$2.21M ﹤0.01% 3302
2025
Q1 		$3.23M Buy
+113,800
New +$4.04M ﹤0.01% 2295
2024
Q2 		– Sell
-10,000
Closed -$1.07M – 5709
2024
Q1 		$1.07M Buy
+10,000
New +$1.01M ﹤0.01% 2970
2023
Q4 		– Sell
-9,000
Closed -$930K – 5802
2023
Q3 		$930K Hold
9,000
– – ﹤0.01% 2583
2023
Q2 		$1.09M Sell
9,000
-32,500
-78% -$4.34M ﹤0.01% 2781
2023
Q1 		$6.37M Buy
41,500
+21,500
+108% +$3.55M ﹤0.01% 1362
2022
Q4 		$3.59M Sell
20,000
-4,000
-17% -$654K ﹤0.01% 1664
2022
Q3 		$2.84M Hold
24,000
– – ﹤0.01% 1907
2022
Q2 		$3.43M Sell
24,000
-105,000
-81% -$15M ﹤0.01% 1747
2022
Q1 		$22.2M Sell
129,000
-60,000
-32% -$10.1M 0.01% 885
2021
Q4 		$48M Buy
189,000
+8,500
+5% +$2.49M 0.03% 575
2021
Q3 		$69.5M Sell
180,500
-71,100
-28% -$26.2M 0.04% 403
2021
Q2 		$59.1M Buy
251,600
+105,000
+72% +$18.8M 0.04% 462
2021
Q1 		$19.2M Buy
146,600
+53,500
+57% +$7.75M 0.01% 979
2020
Q4 		$9.73M Buy
93,100
+6,800
+8% +$688K 0.01% 1576
2020
Q3 		$6.11M Buy
86,300
+73,700
+585% +$5.14M ﹤0.01% 1765
2020
Q2 		$809K Buy
+12,600
New +$690K ﹤0.01% 3783

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup's MRNA Position: Q1 2026 in Review

Citigroup reduced its Moderna (MRNA) stake by 24% in Q1 2026, selling an estimated $21.3M and leaving 1,480,034 shares worth $75.2M. The position accounts for 0.03% of the portfolio, ranked #495.

Citigroup first reported a position in MRNA in Q1 2019 and has held it in 29 quarters since. The position peaked at $280M in Q4 2021. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Citigroup held 1,480,034 shares of Moderna worth $75.2M as of Q1 2026.
  • Citigroup sold 456,479 Moderna shares in Q1 2026, an estimated $21.3M.
  • Moderna made up 0.03% of Citigroup's portfolio in Q1 2026, its #495 holding.
  • Citigroup first reported a position in Moderna in Q1 2019 and has held it in 29 quarters since.
  • Citigroup's Moderna position peaked at $280M in Q4 2021.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.